Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsSecurities - TradableShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Current Deferred Revenue (2022 - 2024)

Historic Current Deferred Revenue for Praxis Precision Medicines (PRAX) over the last 3 years, with Q3 2024 value amounting to $1.2 million.

  • Praxis Precision Medicines' Current Deferred Revenue fell 2461.34% to $1.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.2 million, marking a year-over-year decrease of 2461.34%. This contributed to the annual value of $1.4 million for FY2023, which is 5060.33% down from last year.
  • According to the latest figures from Q3 2024, Praxis Precision Medicines' Current Deferred Revenue is $1.2 million, which was down 2461.34% from $1.2 million recorded in Q2 2024.
  • In the past 5 years, Praxis Precision Medicines' Current Deferred Revenue registered a high of $2.8 million during Q4 2022, and its lowest value of $1.2 million during Q3 2024.
  • Its 3-year average for Current Deferred Revenue is $1.7 million, with a median of $1.5 million in 2023.
  • The largest annual percentage gain for Praxis Precision Medicines' Current Deferred Revenue in the last 5 years was 2461.34% (2024), contrasted with its biggest fall of 5060.95% (2024).
  • Quarter analysis of 3 years shows Praxis Precision Medicines' Current Deferred Revenue stood at $2.8 million in 2022, then plummeted by 50.6% to $1.4 million in 2023, then decreased by 15.95% to $1.2 million in 2024.
  • Its last three reported values are $1.2 million in Q3 2024, $1.2 million for Q2 2024, and $1.3 million during Q1 2024.